What interventions are effective for managing peristomal pyoderma gangrenosum?
Gray
Mikel
M
WOCN Center for Clinical Investigation, and Department of Urology and School of Nursing, University of Virginia, Charlottesville, VA 22908, USA. mg5k@virginia.edu
Catanzaro
Jo
J
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D003646:Debridement; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D015403:Nursing Evaluation Research; D017410:Practice Guidelines as Topic; D017511:Pyoderma Gangrenosum / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy*; D035583:Rare Diseases; D012307:Risk Factors; D012449:Safety; D017592:Skin Care / Q000009:adverse effects / Q000379:methods* / Q000451:nursing; D054047:Surgical Stomas / Q000009:adverse effects*; D016559:Tacrolimus / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D002699:Chlorambucil; D000069285:Infliximab; D016559:Tacrolimus